Patricia Rojas Sánchez1, Africa Holguín2. 1. HIV-1 Molecular Epidemiology Laboratory, Microbiology Department, Hospital Ramón y Cajal-IRYCIS and CIBERESP, Madrid, Spain. 2. HIV-1 Molecular Epidemiology Laboratory, Microbiology Department, Hospital Ramón y Cajal-IRYCIS and CIBERESP, Madrid, Spain africa.holguin@salud.madrid.org.
Abstract
BACKGROUND: Drug resistance monitoring of the paediatric HIV-1-infected population is required to optimize treatment success and preserve future treatment options. OBJECTIVES: To explore the current knowledge of HIV drug resistance (HIVDR) in naive and pretreated HIV-1-infected paediatric populations across diverse settings and sampling time periods. METHODS: PubMed database screened until May 2013. We selected publications including data on transmitted (TDR) and acquired drug resistance mutation (DRM) rates and/or pol sequences for HIVDR testing in paediatric patients. We recorded the children's country, age, study period, number of children with pol sequences, presence or absence of antiretroviral treatment (ART) at sampling time, viral region sequenced, HIVDR rate to the three main drug classes (single, double or triple), the considered resistance mutation list and performed assay, specimen type, HIV-1 variants and subtyping methodology when available. RESULTS: Forty-one selected studies showed HIVDR data from 2538 paediatric HIV-1-infected patients (558 naive and 1980 pretreated) from 30 countries in Africa (11), Asia (6), America (10) and Europe (3). Both TDR and DRM prevalence were reported in 9 studies, only TDR in 6 and only DRM in 26. HIVDR prevalence varied across countries and periods. Most studies used in-house resistance assays using plasma or infected cells. HIV-1 non-B variants were prevalent in 18 paediatric cohorts of the 24 countries with reported subtypes. Only five countries (Uganda, Spain, the UK, Brazil and Thailand) presented resistance data in ≥200 patients. CONCLUSIONS: Systematic and periodic studies among infected children are crucial to design a more suitable first- or second-line therapy.
BACKGROUND: Drug resistance monitoring of the paediatric HIV-1-infected population is required to optimize treatment success and preserve future treatment options. OBJECTIVES: To explore the current knowledge of HIV drug resistance (HIVDR) in naive and pretreated HIV-1-infected paediatric populations across diverse settings and sampling time periods. METHODS: PubMed database screened until May 2013. We selected publications including data on transmitted (TDR) and acquired drug resistance mutation (DRM) rates and/or pol sequences for HIVDR testing in paediatric patients. We recorded the children's country, age, study period, number of children with pol sequences, presence or absence of antiretroviral treatment (ART) at sampling time, viral region sequenced, HIVDR rate to the three main drug classes (single, double or triple), the considered resistance mutation list and performed assay, specimen type, HIV-1 variants and subtyping methodology when available. RESULTS: Forty-one selected studies showed HIVDR data from 2538 paediatric HIV-1-infectedpatients (558 naive and 1980 pretreated) from 30 countries in Africa (11), Asia (6), America (10) and Europe (3). Both TDR and DRM prevalence were reported in 9 studies, only TDR in 6 and only DRM in 26. HIVDR prevalence varied across countries and periods. Most studies used in-house resistance assays using plasma or infected cells. HIV-1 non-B variants were prevalent in 18 paediatric cohorts of the 24 countries with reported subtypes. Only five countries (Uganda, Spain, the UK, Brazil and Thailand) presented resistance data in ≥200 patients. CONCLUSIONS: Systematic and periodic studies among infected children are crucial to design a more suitable first- or second-line therapy.
Authors: Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex Journal: J Clin Microbiol Date: 2015-06-03 Impact factor: 5.948
Authors: Catherine Godfrey; Michael C Thigpen; Keith W Crawford; Patrick Jean-Phillippe; Deenan Pillay; Deborah Persaud; Daniel R Kuritzkes; Mark Wainberg; Elliot Raizes; Joseph Fitzgibbon Journal: J Infect Dis Date: 2017-12-01 Impact factor: 5.226
Authors: Lisa K Poppe; Catherine Chunda-Liyoka; Eun H Kwon; Clement Gondwe; John T West; Chipepo Kankasa; Clement B Ndongmo; Charles Wood Journal: AIDS Date: 2017-08-24 Impact factor: 4.177
Authors: Cissy Kityo; Kim Catherina Eve Sigaloff; Tamara Sonia Boender; Elizabeth Kaudha; Joshua Kayiwa; Victor Musiime; Andrew Mukuye; Mary Kiconco; Immaculate Nankya; Llilian Nakatudde-Katumba; Job C J Calis; Tobias F Rinke de Wit; Peter N Mugyenyi Journal: AIDS Res Hum Retroviruses Date: 2016-02-11 Impact factor: 2.205
Authors: Ragna S Boerma; T Sonia Boender; Kim C E Sigaloff; Tobias F Rinke de Wit; Michael Boele van Hensbroek; Nicaise Ndembi; Titilope Adeyemo; Edamisan O Temiye; Akin Osibogun; Pascale Ondoa; Job C Calis; Alani Sulaimon Akanmu Journal: J Int AIDS Soc Date: 2016-11-10 Impact factor: 5.396
Authors: Maria Letícia Cruz; Edwiges Santos; Maria de Lourdes Benamor Teixeira; Monica Poletti; Carolina Sousa; Maria Isabel Gouvea; Karin Nielsen-Saines; Esaú João Journal: Int J Environ Res Public Health Date: 2016-06-07 Impact factor: 3.390